ERBB2 and breast carcinoma: The drug showed clinical efficacy in the ExteNET study, a Phase III clinical trial where it significantly improved disease-free survival among early-stage patients afflicted with HER2-positive breast cancer who completed adjuvant trastuzumab therapy [51].